Valuation: VISEN Pharmaceuticals

Market Cap 1.26B 1.48B 189M 169M 155M 141M 264M 17.9B 269M 1.85B 746M 9.45B 709M 694M 29.83B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 995M 1.17B 150M 134M 123M 111M 209M 14.16B 213M 1.46B 590M 7.47B 561M 549M 23.61B EV / Sales 2026 *
14.7x
EV / Sales 2027 * 3.93x
Free-Float
28.04%
Yield 2026 *
-
Yield 2027 * -
1 day-2.58%
1 week-12.45%
Current month-2.58%
1 month-26.65%
3 months-29.54%
6 months-49.18%
Current year-58.63%
1 week 12.87
Extreme 12.87
15.01
1 month 12.87
Extreme 12.87
19.9
Current year 12.87
Extreme 12.87
43.3
1 year 12.87
Extreme 12.87
43.3
3 years 12.87
Extreme 12.87
69.15
5 years 12.87
Extreme 12.87
69.15
10 years 12.87
Extreme 12.87
69.15
Manager TitleAgeSince
Chief Executive Officer 60 2018-11-06
Director of Finance/CFO 42 2025-10-12
Chief Tech/Sci/R&D Officer 54 2020-03-31
Director TitleAgeSince
Director/Board Member 60 2018-11-06
Director/Board Member 44 2021-01-07
Director/Board Member 62 2021-03-31
Date Insider Type Main position Quantity % Market Cap. Importance
1/1/26 Other

Chief Executive Officer

108,750 0.0955%
Change 5-day change 1-year change 3-year change Capi.($)
-2.58%-12.45%-64.31% - 194M
-2.37%-5.03%+39.49%+62.39% 63.77B
-2.87%+0.49%+11.11%+69.18% 56.37B
+0.62%+2.11%+16.96%+102.56% 54.62B
-3.33%-5.54%+19.39%+35.69% 44.06B
-2.45%-2.59%+16.36%+98.45% 42.11B
-1.64%+2.32%+219.80%+789.69% 41B
-5.47%+24.76%+101.20%+87.34% 34.92B
+0.21%+1.05%+14.81%+46.96% 32.82B
-2.90%+17.12%-42.35%+337.07% 24.7B
Average -2.28%+5.32%+33.25%+181.04% 39.45B
Weighted average by Cap. -2.16%+4.83%+44.58%+163.55%

Financials

2026 *2027 *
Net sales 67.73M 79.91M 10.18M 9.09M 8.34M 7.59M 14.23M 964M 14.51M 99.66M 40.17M 509M 38.22M 37.41M 1.61B 320M 377M 48.09M 42.93M 39.4M 35.84M 67.19M 4.55B 68.53M 471M 190M 2.4B 180M 177M 7.59B
Net income - -
Net Debt -262M -309M -39.44M -35.21M -32.31M -29.39M -55.11M -3.73B -56.21M -386M -156M -1.97B -148M -145M -6.22B 486K 573K 73.09K 65.25K 59.88K 54.47K 102K 6.92M 104K 715K 288K 3.65M 274K 268K 11.53M
Projected Income Statement - Annual - VISEN Pharmaceuticals
Logo VISEN Pharmaceuticals
Visen Pharmaceuticals is a holding company mainly engaged in developing and commercializing disruptive endocrine therapies. The Company's main products under development include lonapegsomatropin, navepegritide, and palopegteriparatide. The lonapegsomatropin is used to treat growth hormone deficiency in children aged 3 to 17 years old. The navepegritide is a disease repair therapy used to treat children with cartilage dysplasia aged 2 to 10 years old. The palopegteriparatide is a treatment method used to treat adult hypoparathyroidism. The Company is in the late stage of research and development, and its products are close to commercialization.
Employees
102
Date Price Change Volume
26-11-02 HK$13.57 -2.58% 2,400
26-10-30 HK$13.93 -0.50% 28,000
26-10-29 HK$14.00 -1.96% 15,700
26-10-28 HK$14.28 -4.80% 2,400
26-10-27 HK$15.00 -3.23% 9,500
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
11.50CNY
Average target price
42.85CNY
Spread / Average Target
+272.54%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - VISEN Pharmaceuticals
  1. Stock Market
  2. Stocks
  3. 2561 Stock